A multi-site clinical trial, known as preFRIEND (NCT04177693), evaluate the liver safety of a green tea extract in women under the age of 40 while receiving fertility promoting drugs.
Green tea and the green tea catechin EGCG have been studied in other diseases including prostate cancer chemoprevention – you can find a review article here.
This work was recently published with the abstract and full-length article available here.
Briefly, this multi-site clinical trial enrolled patients from UIC, University of Chicago, Yale, and Johns Hopkins.
Liver safety was evaluated after 30 days and no participants experienced any form of drug induced liver injury.
This clinical trial has now been expanded to a larger clinical trial known as FRIEND (NCT05364008) and is estimated to enroll 200 human participants.
Reference:
Siblini H, Al-Hendy A, Segars J, González F, Taylor HS, Singh B, Flaminia A, Flores VA, Christman GM, Huang H, Johnson JJ, Zhang H. Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women. Nutrients. 2023 Jan 9;15(2):320. doi: 10.3390/nu15020320.
